Pfizer Has a Phase 3 Win for ELREXFIO. It Still Has Not Shown the Math.

Pfizer just said its myeloma drug worked in a Phase 3 trial. For anyone outside biotech, the translation is simple: the company is trying to move a late-line cancer drug into earlier treatment, where far more patients are treated and far more money is made. The problem is that Pfizer released the adjective, not the math.

The company said ELREXFIO improved progression-free survival, meaning patients lived longer before their multiple myeloma got worse, against a standard three-drug regimen. But it did not publish the hazard ratio, the median benefit, or the safety tables that would tell doctors whether this was a real competitive result or just a positive topline on the way to a filing.

According to Pfizer, the Phase 3 MagnetisMM-5 study showed a statistically significant and clinically meaningful improvement in progression-free survival versus daratumumab plus pomalidomide and dexamethasone. Endpoints News first reported the result. Pfizer also said overall survival, a measure of whether patients live longer overall, was not yet mature at this interim look.

ELREXFIO, also called elranatamab, is a bispecific antibody, a lab-made protein built to grab two targets at once. Pfizer says it binds BCMA, a marker on myeloma cells, and CD3 on T cells, the immune cells that kill infected or malignant cells. The idea is to pull a patient's own immune cells directly into contact with the cancer.

That matters because ELREXFIO is already on the market, but only for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Pfizer's 2023 announcement of accelerated US approval said that approval rested on the single-arm Phase 2 MagnetisMM-3 trial, which meant the company still needed a randomized confirmatory study. MagnetisMM-5 is that study, and Pfizer said it plans regulatory submissions in 2026.

The missing numbers matter because this is a crowded and unforgiving corner of blood-cancer treatment. ELREXFIO belongs to a class of off-the-shelf immune drugs that try to redirect T cells without the custom manufacturing step required for CAR-T therapy, a personalized cell treatment made from a patient's own immune cells. The real question is how strong the underlying result was, and what patients had to trade for it.

A recent rival benchmark shows why. The ASCO Post reported that Johnson & Johnson's BCMA bispecific teclistamab, combined with daratumumab, cut the risk of disease progression or death by 83% in the Phase 3 MajesTEC-3 trial and cut the risk of death by 54% against daratumumab-based regimens. The same report said grade 3 or 4 infections occurred in 54.1% of patients on the teclistamab combination.

That does not mean ELREXFIO needs to match teclistamab point for point. It does mean a bare announcement is not enough to judge where Pfizer stands. In myeloma, the difference between a useful label expansion and a regimen that actually changes practice usually lives in the tables: the size of the progression-free survival benefit, the subgroup breakdowns, and the toxicity burden.

Pfizer's own source trail also leaves a few loose edges. The new press release says MagnetisMM-5 enrolled 497 patients across 26 countries who had received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. An accessible trial-registry mirror hosted by UCSF describes MagnetisMM-5 as a three-arm randomized Phase 3 study of elranatamab alone or with daratumumab versus daratumumab, pomalidomide and dexamethasone. Pfizer's topline release emphasized the comparison against the standard regimen, but it did not spell out how the other arm performed.

There is also a smaller discrepancy in the public record. In Pfizer's 2023 approval announcement, the company said the confirmatory MagnetisMM-5 trial involved 854 patients. The new release says 497 patients enrolled. That may reflect the difference between an older enrollment target and the population actually enrolled or analyzed, but Pfizer did not explain it in the new statement.

Another reason to be careful with cross-trial comparisons is patient mix. The ASCO Post quoted myeloma specialist Noopur Raje saying MajesTEC-3 was run in an almost entirely daratumumab-naive population, with only 5% of patients previously exposed to daratumumab. So even dramatic numbers from one study do not automatically travel cleanly into another.

Pfizer now has a positive confirmatory readout and a path to ask regulators for an earlier-line expansion. It still has not given the public the evidence package needed to judge whether ELREXFIO is merely staying in the game or making a serious competitive statement.